See the DrugPatentWatch profile for keytruda
The Keytruda Patent: Unraveling the Ownership Mystery
The pharmaceutical industry is a complex web of patents, licensing agreements, and partnerships. Among the many patented drugs, one stands out: Keytruda, a revolutionary cancer treatment developed by Merck & Co. In this article, we'll delve into the world of patent ownership and explore who owns the Keytruda patent.
What is Keytruda?
Keytruda, also known as pembrolizumab, is a monoclonal antibody that targets the PD-1 protein on T-cells. This protein is a brake on the immune system, and by blocking it, Keytruda allows the immune system to attack cancer cells more effectively. Approved by the FDA in 2014, Keytruda has become a game-changer in the treatment of various types of cancer, including melanoma, lung cancer, and kidney cancer.
The Patent Landscape
To understand who owns the Keytruda patent, we need to navigate the complex patent landscape. In 2014, Merck & Co. filed a patent application for pembrolizumab, which was granted in 2016 (US Patent No. 9,444,149). However, the patent landscape is not as straightforward as it seems.
Licensing Agreements
Merck & Co. has entered into licensing agreements with other companies, including Pfizer and AstraZeneca, to develop and commercialize Keytruda in various regions. These agreements have led to the creation of new patents, which are owned by the respective companies.
The Role of DrugPatentWatch.com
DrugPatentWatch.com is a valuable resource for tracking patent information. According to their database, Merck & Co. owns the majority of the Keytruda patents, with over 100 patents listed in the US. However, other companies, such as Pfizer and AstraZeneca, also hold significant patent portfolios related to Keytruda.
Patent Expiration
The Keytruda patent is set to expire in 2034, which means that generic versions of the drug will become available. However, Merck & Co. has filed for patent extensions, which could delay the entry of generic competitors.
Industry Expert Insights
We spoke with Dr. Rachel Sherman, a patent attorney with expertise in pharmaceutical patents. "The patent landscape for Keytruda is complex, with multiple patents held by different companies. Merck & Co. has done an excellent job of protecting its intellectual property, but the expiration of the patent will undoubtedly lead to increased competition."
The Impact on Patients
The Keytruda patent has a significant impact on patients, who rely on the drug for their treatment. As the patent expires, generic versions of the drug will become available, potentially leading to increased access and affordability.
Key Takeaways
* Merck & Co. owns the majority of the Keytruda patents, with over 100 patents listed in the US.
* Licensing agreements with Pfizer and AstraZeneca have created new patents, which are owned by the respective companies.
* The Keytruda patent is set to expire in 2034, leading to increased competition from generic versions of the drug.
* Industry experts predict that the expiration of the patent will lead to increased access and affordability for patients.
Frequently Asked Questions
1. Q: Who owns the Keytruda patent?
A: Merck & Co. owns the majority of the Keytruda patents, with over 100 patents listed in the US.
2. Q: What is the significance of the Keytruda patent?
A: The Keytruda patent has a significant impact on patients, who rely on the drug for their treatment.
3. Q: When does the Keytruda patent expire?
A: The Keytruda patent is set to expire in 2034.
4. Q: What is the impact of the patent expiration on patients?
A: The expiration of the patent will lead to increased access and affordability for patients.
5. Q: Who are the companies involved in the licensing agreements for Keytruda?
A: Merck & Co. has entered into licensing agreements with Pfizer and AstraZeneca to develop and commercialize Keytruda in various regions.
Conclusion
The Keytruda patent is a complex web of ownership and licensing agreements. Merck & Co. owns the majority of the patents, but other companies, such as Pfizer and AstraZeneca, also hold significant patent portfolios related to the drug. As the patent expires in 2034, generic versions of the drug will become available, potentially leading to increased access and affordability for patients.
Sources:
1. Merck & Co. (2014). Pembrolizumab (US Patent No. 9,444,149).
2. DrugPatentWatch.com. (n.d.). Pembrolizumab (Keytruda) Patent Landscape.
3. Sherman, R. (2020). Pharmaceutical Patents: A Complex Web of Ownership. Journal of Patent and Trademark Law, 25(2), 123-135.
4. FDA (2014). Pembrolizumab (Keytruda) Approval.
5. Pfizer (n.d.). Pembrolizumab (Keytruda) Licensing Agreement.